Search
for
Sort by
Research 181–210 of 1000+
- 5α‐Reductase Inhibitors
- Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
- Type 2 Diabetes, Metabolic Syndrome and Lipid Metabolism
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Incidence of alopecia from endocrine therapies in cancer
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
- Adverse effects of sports supplements in men
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Dermatologic Adverse Events from Cancer Treatments
- Adverse effects of common medications on male fertility
- Adverse Cutaneous Reactions to Antipsychotics
- Adverse Cutaneous Reactions to Antidepressants
- Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Increased Incidence of Telogen Effluvium Following Platelet-Rich Plasma Therapy in Patients with Elevated TNF-α Expression: A Prospective Cohort Study
- Incidental benefits after fecal microbiota transplant for ulcerative colitis
- Reporting on Adverse Clinical Events
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Prevalence and Partern of Early Adverse Reactions in Cancer Patients Receiving Chemotherapy at Ocean Road Cancer Institute
- Air pollution and skin diseases: Adverse effects of airborne particulate matter on various skin diseases